- Home
- ZNTL vs CGTX Comparison
ZNTL vs CGTX Comparison
Compare ZNTL & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | CGTX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 132.4M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | CGTX |
|---|---|---|
| Price | $3.25 | $1.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $5.87 | $3.33 |
| AVG Volume (30 Days) | ★ 2.4M | 914.7K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $26,865,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $0.22 |
| 52 Week High | $3.95 | $3.83 |
Technical Indicators
Market Signals| Indicator | ZNTL | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.76 | 49.68 |
| Support Level | $2.80 | $1.37 |
| Resistance Level | $3.95 | $1.51 |
| Average True Range (ATR) | 0.42 | 0.10 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 70.91 | 54.35 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.